Dr. Minal Barve, MD
Claim this profileMary Crowley Cancer Research
Expert in Solid Tumors
Expert in Tumors
46 reported clinical trials
71 drugs studied
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Tumors
Global LeaderStage IV
Stage III
MMR positive
Affiliated Hospitals
Mary Crowley Cancer Research
Mary Crowley Cancer Research Center
Clinical Trials Minal Barve, MD is currently running
EU101
for Solid Cancers
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Recruiting1 award Phase 1 & 210 criteria
BDTX-1535 + Temozolomide
for Glioblastoma and Lung Cancer
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma multiforme (GBM) expressing EGFR alterations (Phase 1 only). All patients will self administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
Recruiting1 award Phase 1 & 214 criteria
More about Minal Barve, MD
Clinical Trial Related3 years of experience running clinical trials · Led 46 trials as a Principal Investigator · 24 Active Clinical TrialsTreatments Minal Barve, MD has experience with
- Pembrolizumab
- Niraparib
- Docetaxel
- Retifanlimab
- SV-BR-1-GM
- Gemcitabine
Breakdown of trials Minal Barve, MD has run
Tumors
Non-Small Cell Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Minal Barve, MD specialize in?
Minal Barve, MD focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Minal Barve, MD currently recruiting for clinical trials?
Yes, Minal Barve, MD is currently recruiting for 24 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Minal Barve, MD has studied deeply?
Yes, Minal Barve, MD has studied treatments such as Pembrolizumab, Niraparib, Docetaxel.
What is the best way to schedule an appointment with Minal Barve, MD?
Apply for one of the trials that Minal Barve, MD is conducting.
What is the office address of Minal Barve, MD?
The office of Minal Barve, MD is located at: Mary Crowley Cancer Research, Dallas, Texas 75230 United States. This is the address for their practice at the Mary Crowley Cancer Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.